You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Praluent

Showing 1 - 25 of 46
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nephrotic Syndrome Trial in Dallas (Alirocumab, Alirocumab , Atorvastatin)

Terminated
  • Nephrotic Syndrome
  • Dallas, Texas
    DallasVAMC
Aug 17, 2022

Vasculopathy Trial in Stanford (alirocumab, )

Enrolling by invitation
  • Vasculopathy
  • alirocumab
  • placebo
  • Stanford, California
    Stanford University
May 22, 2022

Stroke, Acute Ischemic, PCSK9 Inhibitor Trial in Seoul (Alirocumab)

Not yet recruiting
  • Stroke, Acute Ischemic
  • PCSK9 Inhibitor
  • Seoul, Korea, Republic of
    Asan Medical Center
Oct 9, 2023

Sepsis Trial in Atlanta (Alirocumab, Placebo)

Not yet recruiting
  • Sepsis
  • Atlanta, Georgia
  • +1 more
Jul 19, 2022

Hypercholesterolemia, Cardiovascular Diseases Trial in Cincinnati (lerodalcibep, evolocumab, alirocumab)

Active, not recruiting
  • Hypercholesterolemia
  • Cardiovascular Diseases
  • lerodalcibep
  • +2 more
  • Cincinnati, Ohio
  • +2 more
Jul 13, 2022

Intracranial Atherosclerosis, Acute Ischemic Stroke, ICAS - Intracranial Atherosclerosis Trial in Chiayi City (Alirocumab)

Recruiting
  • Intracranial Atherosclerosis
  • +2 more
  • Chiayi City, Taiwan
    Yenchu Huang
Nov 29, 2022

Prospective German Very High Cardiovascular Risk Patients

Recruiting
  • Dyslipoproteinemias
  • PCSK9 Inhibitor [EPC]
  • Standard lipid lowering therapy
  • Dresden, Germany
    Medizinische Klinik und Poliklinik III
Mar 18, 2022

Praluent® Pregnancy Exposure Registry: An OTIS Pregnancy

Terminated
  • Hypercholesterolemia
  • ALIROCUMAB SAR236553 (REGN727)
  • San Diego, California
    Investigational site UNITED STATES
Nov 19, 2020

Efficacy of Treatment With PCSK9 Inhibitors in Italy

Completed
  • Hypercholesterolemia
  • Repatha (evolocumab); Praluent (alirocumab)
  • Bari, Italy
  • +8 more
Jun 20, 2022

Acute Coronary Syndrome Trial (Repatha or Praluent)

Not yet recruiting
  • Acute Coronary Syndrome
  • Repatha or Praluent
  • (no location specified)
Sep 13, 2021

Atherosclerosis, Cardiovascular Diseases Trial in Cambridge (Alirocumab 150 MG/ML, Ezetimibe 10Mg Tablet, Atorvastatin 40Mg

Active, not recruiting
  • Atherosclerosis
  • Cardiovascular Diseases
  • Alirocumab 150 MG/ML
  • +6 more
  • Cambridge, Cambridgeshire, United Kingdom
    Addenbrooke's Hospital
Jul 22, 2021

Saphenous Vein Graft Atherosclerosis Trial in United States (Alirocumab 150 MG/ML subcutaneous injection, Matching Placebo

Terminated
  • Saphenous Vein Graft Atherosclerosis
  • Alirocumab 150 MG/ML subcutaneous injection
  • Matching Placebo subcutaneous injection
  • San Francisco, California
  • +3 more
Sep 15, 2021

Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia Trial in Worldwide (Praluent)

Terminated
Has Results
  • Heterozygous Familial Hypercholesterolemia
  • Non-familial Hypercholesterolemia
  • Praluent
  • Auburn, Alabama
  • +123 more
May 20, 2021

Hypercholesterolemia Trial in Worldwide (Praluent (Alirocumab), Placebo)

Completed
Has Results
  • Hypercholesterolemia
  • Praluent (Alirocumab)
  • Placebo
  • Auburn, Alabama
  • +188 more
Apr 14, 2021

Homozygous Familial Hypercholesterolemia Trial in Worldwide (Alirocumab, Placebo)

Completed
Has Results
  • Homozygous Familial Hypercholesterolemia
  • Boca Raton, Florida
  • +27 more
Jun 7, 2021

Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage Trial in Salt Lake City (Alirocumab, Placebo)

Terminated
  • Stroke
  • +2 more
  • Salt Lake City, Utah
    University of Utah
Apr 18, 2020

Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia Trial in Canada, United States (Alirocumab, Placebo Matched to

Completed
Has Results
  • Hypercholesterolemia
  • Heterozygous Familial Hypercholesterolemia
  • Mission Viejo, California
  • +13 more
Jul 19, 2020

Hemodialysis, Peritoneal Dialysis, Hypercholesterolemia Trial in Dallas (Alirocumab 150 MG/ML [Praluent])

Unknown status
  • Hemodialysis
  • +3 more
  • Alirocumab 150 MG/ML [Praluent]
  • Dallas, Texas
    Baylor Soltero CV Research
Feb 10, 2020

Heterozygous Familial Hypercholesterolemia Trial in Germany, United States (Placebo, Alirocumab)

Completed
Has Results
  • Heterozygous Familial Hypercholesterolemia
  • Aurora, Colorado
  • +12 more
Apr 21, 2020

Hypercholesterolaemia Trial in Worldwide (Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin)

Active, not recruiting
  • Hypercholesterolaemia
  • Alirocumab SAR236553 (REGN727)
  • +12 more
  • Boca Raton, Florida
  • +45 more
Jan 12, 2022

Hypercholesterolemia Trial in France, United States (Alirocumab, Placebo)

Completed
Has Results
  • Hypercholesterolemia
  • Salt Lake City, Utah
  • +3 more
Jun 4, 2020

Familial Hypercholesterolemia Trial in Madrid (Alirocumab)

Completed
  • Familial Hypercholesterolemia
  • Madrid, Spain
    Fundacion Hipercolesterolemia Familiar
Jul 15, 2022

Myocardial Infarction, Hypercholesterolemia Trial in Richmond (alirocumab, )

Completed
Has Results
  • Myocardial Infarction
  • Hypercholesterolemia
  • Richmond, Virginia
    Virginia Commonwealth University
Aug 15, 2019

Hypercholesterolemia, Acute Coronary Syndrome Trial in Japan (Alirocumab SAR236553, Atorvastatin, Rosuvastatin)

Completed
Has Results
  • Hypercholesterolemia
  • Acute Coronary Syndrome
  • Alirocumab SAR236553
  • +7 more
  • Bunkyō-Ku, Japan
  • +38 more
Jul 26, 2019

Atherosclerosis, Hyperlipidemia Trial in Beverly Hills (Alirocumab)

Unknown status
  • Atherosclerosis
  • Hyperlipidemia
  • Beverly Hills, California
    Westside Medical Associates of Los Angeles
Apr 24, 2019